Anxiety and depression are devastating mental illnesses that are a significant public health concern. Selective serotonin-reuptake inhibitors are the first-line treatment strategy for these disorders, which despite being a significant advantage over older treatments, are hampered by a limited efficacy in a significant subset of patients, delayed onset of action and side effects that affect compliance. Thus, there is much impetus to develop novel therapeutic strategies. However, this goal can only be rationally realised with a better understanding of the molecular pathophysiology of these disorders. MicroRNAs (miRNAs) are a newly discovered class of gene-expression regulators that may represent a novel class of therapeutic targets to treat a variety of disorders including psychiatric diseases. miRNAs are heavily involved in regulating many physiological processes including those fundamental to the functioning of the central nervous system. Evidence collected to date has already demonstrated that miRNA-expression levels are altered in patients suffering from depression and anxiety and in pre-clinical models of psychological stress. Furthermore, increasing evidence suggests that psychoactive agents including antidepressants and mood stabilisers utilise miRNAs as downstream effectors. Altering miRNA levels has been shown to alter behaviour in a therapeutically desirable manner in pre-clinical models. This review aims to outline the evidence collected to date demonstrating miRNAs role in anxiety and depression, the potential advantages of targeting these small RNA molecules as well as some of the hurdles that will have to be overcome to fully exploit their therapeutic potential.
Anxiety and depression are devastating mental illnesses creating a severe burden on individuals and society. It is estimated 9.5% of the US population will reach the criteria for diagnosis of a mood disorder in any given 12 months, whereas this figure is as high as 18.1% for anxiety disorders. 1 Moreover, the World Health Organisation has predicted by 2020, unipolar depression will become the leading cause of disease burden in developed countries (www.who.int/ mental_health/management/depression/definition/en/ index.html). Currently, the vast majority of drugs indicated for the treatment of mood disorders target the monoamine system, increasing the amount of the neurotransmitters serotonin and/or noradrenaline available for signalling in the synaptic cleft. [2] [3] [4] [5] The limitations of such agents include a delayed onset of action (weeks-months), 6 a significant percentage of non-responders 7, 8 and side effects. 9, 10 Although there have been some advances, such as the development of the selective serotonin-reuptake inhibitors, which carry a lower side-effect profile than their predecessors, there has been almost no advancement in the basic mechanism employed by antidepressants since the introduction of the monoamine oxidase inhibitors in the 1950s.
The current state of pharmacological interventions for the treatment of pathological anxiety is equally as sobering with little progress made in the five decades that have passed since the introduction of the benzodiazepines in the 1960s. [11] [12] [13] Currently available treatments mainly target the serotonergic and GABAergic neurotransmitter systems; 11, 14 again these are of limited efficacy in a significant proportion of the population and also can produce unwanted side effects especially dependence.
14 As such, there is an unmet medical need for the development of new antidepressant and anxiolytic drugs with novel mechanisms of action. Accordingly, basic research and drug discovery efforts have begun to move away from this focus on the monoaminergic systems and other potential mechanisms are increasingly being considered. Examples of this includes the growing corpus of data demonstrating the involvement of deficits in cellular plasticity and resilience as contributors to the onset of depression (for extensive reviews see ref. 15, 16) . This is reflected by the facts that several drugs targeting plasticity and neurotrophic cascades are currently in various stages of clinical trials. 16 Furthermore, disruptions to circadian rhythm is commonly seen in depressed patients and is considered to be a contributory factor to the onset of depression. 17, 18 Agomelatine, one of the first nonaminergic-based pharmacotherapies approved for use in major depression, 19 targets the melatonergic system, a key synchroniser of circadian rhythm. 20 Additional neurotransmitters aside from the monoamines are also being investigated as potential targets for the treatment of depression, one such example is the glutamatergic system, which is becoming the focus of much research into affective disorders. [21] [22] [23] Interestingly, case studies have already demonstrated the capacity of riluzole, which targets the glutamate transporter to alleviate depressive symptoms. 24, 25 Research efforts focused on developing anxiolytics aimed at previously unexploited targets includes research centred on the endocannabinoid system, 26 substance P 27 and neuropeptide Y [28] [29] [30] among others. Despite this recognition of the need to move away from the previous overt focus on monoamines, several barriers remain that retard drug discovery efforts. The paucity of knowledge regarding the molecular pathophysiological mechanisms that underlie such mental illnesses, and indeed the incomplete understanding of the therapeutically relevant molecular mechanisms employed by currently available therapeutics are hampering the development of such novel treatment strategies. 13, 31 MicroRNAs (miRNAs)
Introduction
In recent years it has become increasingly clear that in addition to traditional regulatory mechanisms, such as transcription factor-mediated expression and alternative splicing, gene expression is also regulated through the activity of non-coding small RNAs. To date the best characterised of these small RNAs are miRNAs. Originally discovered when a gene, Lin-4, known to control larval development in C. elegans was found to be a non-coding RNA transcript. 32 Additional work went on to show Lin-4 represses the activity of a protein-coding gene, Lin-14, through sequence-specific binding to the 3 0 UTR (untranslated region) of its mRNA. 33 From these original experiments, the field of miRNAs was born and since then they have to come to the fore as crucial regulators of gene expression involved in a staggering number of physiological processes. [34] [35] [36] [37] [38] [39] [40] [41] [42] miRNAs are small (B22 nt) non-coding RNA transcripts. They mediate their regulatory effects by binding to the 3 0 UTR of mRNAs and targeting them for degradation or by steric hindrance, which prevents access of the cells translation machinery to the mRNA. 43, 44 Additionally, it has been shown that miRNAs have the potential to increase translation of its mRNA targets, however this appears to be much less common. 45 The majority of miRNA genes discovered are located in regions of the genome distal to previously annotated genes, suggesting their expression is under the control of their own regulatory elements 46 ,47 whereas about 25% have been shown to be in the intronic regions of pre mRNAs. 48 These miRNAs may share transcriptional-control mechanisms with their mRNA 'hosts' leading to a synchronised expression. As mentioned, miRNAs are key regulators of eukaryotic gene expression, with estimates of up to 30% of mammalian mRNA transcripts being subject to regulation from miRNAs. 43 Furthermore, miRNA sequences show a remarkable level of evolutionary stability, suggesting they are crucial to correct physiological functioning. 49 miRNAs show a highly regulated expression both temporally and spatially, which contributes to the unique geneexpression profile in a certain region at a certain time. [50] [51] [52] In this way, miRNAs contribute to the development and maintenance of a specific transcriptome particularly suited to a particular tissue at a specific developmental time point. Early work in C.elegans suggests that cellular levels of individual miRNA molecules are much larger than other RNAs, such as U6 RNA and mRNAs, again highlighting their importance in controlling cellular levels of gene expression. 53 miRNA biogenesis miRNAs have promoters which mainly interact with RNA polymerase II and transcription factors similar to the promoters of protein-coding genes. [54] [55] [56] The initial product of transcription of a miRNA gene is a long RNA transcript known as a pri-miRNA ( Figure 1 ). This pri-miRNA then undergoes nuclear processing performed by the type-III endonuclease Drosha to produce one or several pre-miRNAs, which are B60-110 nt long transcripts that form hairpin structures. 57, 58 Also like protein-coding mRNAs, primiRNAs are capped and polyadenylated with differing post-transcriptional-processing steps affecting stability. 59 pre-miRNAs are then exported to the cytoplasm via the exportin5-Ran GTP complex 60, 61 where they undergo further processing by Dicer, another type-III endonuclease. [62] [63] [64] [65] Dicer-induced cleavage results in the mature miRNA containing a 5 0 phosphate and a 3 0 2 nt overhang and a similar structure made from the opposing strand. 48 The miRNA is then incorporated into the RNA-induced silencing complex (RISC), which allows it to mediate its gene-regulatory activity. The strand with the less thermodynamically stable 5 0 end is usually chosen as the lead strand and incorporated into the ribonucleoprotein complex, whereas the other strand (passenger strand) is degraded. 66 
Mechanisms of miRNA-induced regulation
The central catalytic component of RISC is the protein Argonaute 2, which has endonuclease activity directed against mRNAs. 67, 68 Currently, the accepted model details miRNA-induced repression of mRNA translation following one of two paths depending on the level of sequence complementarity between the miRNA and mRNA target. If there is a sufficiently high level of complementarity between the RISCincorporated miRNA and the target mRNA then cleavage and degradation of the mRNA will occur, however if the level of complementarity is below a certain threshold then blockade of translation through steric hindrance occurs. 69, 70 This adds another layer to the scope of gene regulation afforded by miRNAs with levels of sequence complementarity to the mRNA dictating if an mRNA is degraded or if translation is simply inhibited which can be relieved at a different time point. This allows a single miRNA to have vastly different effects on mRNA targets in a sequence-dependent manner. An additional feature of miRNAs that increases its regulatory capacity is the fact that multiple binding sites for many different miRNAs can exist within the 3 0 UTR of a single transcript and a particular miRNA can bind to sites on the 3 0 UTRs on many different mRNAs. 44, 71 It has been estimated that each miRNA can regulate hundreds of individual transcripts. 36 This complex structure of gene regulation makes miRNAs particularly attractive therapeutic drug targets as one miRNA can affect entire gene networks and indeed this may be a particularly attractive strategy for treating complex disorders, such as depression and anxiety, where subtle changes to various components of a particular system may be effective. Indeed, in psychiatry there has been a recent departure from having drugs that are very selective for one therapeutic target towards drugs that may have multiple actions. 72 However, this poses major problems in rational drug discovery efforts. Thus, miRNA-based targets are beginning to offer themselves as potential strategy to overcome this hurdle.
Measuring miRNA function
Since their discovery almost two decades ago, our understanding of miRNA function has proceeded rapidly. This has been partly due to the adaptation of technology originally designed to study the function of larger RNA molecules, which has been sufficiently adapted to allow analysis of miRNA function (see Figure 2) . Indeed, the rapid elucidation of the pathway used by miRNAs to mediate their regulatory effects proceeded relatively rapidly, due to the latter steps being almost identical to those used by small interfering RNAs (siRNAs). Much of the work that will be discussed in detail below uses microarrays specifically designed for measuring relative miRNA quantity within a particular tissue. These consist of short oligonucleotides displaying complementary sequences to known miRNAs spotted onto a chip. Fluorescently labelled miRNAs will bind to these oligonucleotides based on sequence complementarity, and can be visualised using photo-sensitive lasers and processing software. This allows the comparison of multiples (1000 s) of miRNAs between two different samples, for example, control versus disease state or control versus drug treated. This facilitates 'fishing' experiments where researchers can identify changes to miRNA levels due to a disease state or drug treatment. These miRNAs can then be prioritised for follow-up study using modified quantitative reverse transcriptase-PCR to verify these changes. Following from these experiments, researchers have begun to alter miRNA-expression levels Figure 1 Biogenesis of microRNAs (miRNAs). miRNA genes are transcribed by RNA polymerase II producing a pri-miRNA. The pri-miRNA is then processed by Drosha to produce hairpin structures called pre-miRNAs. Pre-miRNAs are then exported from the nucleus to the cytoplasm via the exportin5-Ran complex. In the cytoplasm, they are further processed by Dicer producing the mature miRNA. The mature miRNA is then incorporated into the RNA-induced silencing complex (RISC). The miRNA-RISC complex is then able to repress translation in a sequence-specific manner either through degradation of the target mRNA or by blocking access of the cells' translational machinery to the mRNA. directly in cell lines and more recently in vivo to further characterise the functions of particular miRNAs. Genetic-association studies have also been utilised to explore the role miRNAs may have in disease states. Linking polymorphisms present in the regulatory regions governing miRNA expression to disease states would not only initially suggest a role for that particular miRNA in a disease state, but may also be effective tool used for predicting an individuals likelihood in developing a particular disorder.
Essential to the study of miRNAs and their role in various disease processes has been the development of various bioinoformatic tools designed to facilitate functional research into miRNAs. miRBase (www.mirbase.org), the central depositary for miRNA data, acts as the central database and arbiter of nomenclature for experimentally verified miRNAs. 59 Through the website, primary and mature sequence data and genomic data can be accessed as well as data regarding the original discovery and publication of each experimentally verified miRNA. This database has facilitated the swift growth of the miRNA field ensuring all researchers are working off the same sequence data and allowing for a uniform nomenclature to facilitate communication. As discussed above, miRNAs bind and repress their mRNA targets based on sequence complementarity between the two nucleic acids. Different levels of complementarity are required between different regions of the miRNA and mRNA with the seed region (nt 1-8 on the miRNA), requiring full complimentarity and different parts of the transcript requiring varying levels of complementartity. [73] [74] [75] [76] [77] Various algorithms (for example, TargetScan (www.targetscan.org) PicTar (pictar.mdc-berlin.de), miRanada (www.microrna.org) to name only a few) have been developed, which predict the likelihood of a particular miRNA regulating an mRNA based on sequence data as well as additional data including evolutionary sequence conservation. 76, 78 Using these tools to predict the potential of a miRNA to regulate an mRNA allows for rapid selection of potential mRNAs for follow-up and confirmatory analysis once a particular miRNA is shown to be altered in a particular experimental treatment. This has greatly accelerated research into miRNAs and the potential biological pathways in which they act and will be invaluable in moving miRNAs from the bench to the bedside. Figure 2 Common experimental strategies in the search for miRNAs that have the potential to serve as therapeutic targets for depression and anxiety disorders. Differential microRNA expression can be identified from different experimental groups (for example, non-disease state versus disease state or non-treated versus treated) obtained from patients, pre-clinical models or originate from an in vitro source. A micorarray can be used to assess differences in the levels of a large number of different miRNAs between the different experimental groups. The results obtained will then need to be verified using quantitative reverse transcriptase PCR (qRT-PCR). Alternatively, a researcher may chose to use bioinformatic algorithms to prioritise a single or a particular set of miRNAs for analysis via qRT-PCR (for example, based on predicted miRNA effectors of a gene of interest (GOI)). The miRNAs whose differential expression between groups which have been verified through qRT-PCR, can then be analysed using in vitro assays to confirm target predictions or move directly to pre-clinical models to predict potential antidepressant or anxiolytic behaviour. From this, individual miRNAs can be prioritised for follow-up work to confirm their potential therapeutic potential.
The role of miRNAs in the central nervous system (CNS)
It is becoming more obvious that miRNAs are involved in the control and maintenance of almost every aspect of normal physiological functioning with the CNS being no exception. Early work using zebrafish demonstrated the miRNA processor Dicer is essential to correct development of numerous tissues including the brain, with injection of mature miR-430 rescuing brain defects in these mutants demonstrating that miRNAs have an essential role in neuronal developmental. 79 Specifically, miR-133b has been shown to be essential for correct maturation of dopaminergic neurons. 80 In addition to being essential for neuronal development, post-mitotic neurons have been shown to express Dicer, suggesting miRNAs are not only involved in neuronal developmental but are also required for continued maintenance of neuronal phenotype. 81 Furthermore, an absence of Dicer leads to cell death showing miRNAs are essential for continuous cell survival. 82 These data demonstrate the crucial nature of miRNA's involvement in the fundamental process of neuronal differentiation and maintenance.
Neurogenesis is an important process in learning and memory [83] [84] [85] and has been linked to psychiatric disorders. 86 Again miRNAs appear to be at the forefront in regulating this essential process. miR-124-mediated repression of the transcription factor Sox9 is essential for the progression of stem cells in the sub-ventricular zone into fully developed neurons 87 and another miRNA, miR-137, is also involved in the development of neural stem cells into mature neurons. 88 Clearly, miRNAs control the birth of new neuronal cells and interestingly the concept of antidepressants mediating part of their benefit through neurogenesis is coming more to the fore in research. 89, 90 By targeting miRNAs, a more direct route to inducing neurogenesis may be possible.
Synaptic plasticity is an essential process facilitating learning and memory and disruption may lead to psychiatric disorders. Early evidence for the role miRNAs have in plasticity came from work which showed Fragile-X mental retardation protein, which is a synaptic translational repressor, interacts with miRNAs and components of the RISC pathway including Dicer and Argonaute 1. 91 Further work showed components of the RISC pathway are essential for synaptic protein synthesis highlighting miRNAs involvement in synaptic plasticity.
92 miR-134 is localised to the synaptodendritic compartment of rat hippocampal neurons and regulates Limk1, which itself regulates the size of dendritic spines that are sites of postsynaptic excitatory transmission. 93 Studies since have demonstrated specific miRNAs are enriched in synapses and control local protein synthesis and likely have a role in plasticity. 94, 95 Although the field is still relatively in its infancy, early data is placing miRNAs right at the centre of many of the fundamental processes that underscore correct functioning of the CNS. Disruptions to these processes have been linked to the development of anxiety and depression, 15, 86, 96 and it is likely that miRNAs fine tune these biological functions through subtle yet additive effects on mRNA functions. Dysregulation of miRNA function would lead to incorrect regulation of their mRNA targets leading to incorrect physiological functioning in a whole host of systems. By targeting this aberrant miRNA functioning, therapeutic benefits may be possible.
Obstacles encountered in attempts to utilise nucleic acids for therapeutic purposes
Despite the promise and excitement generated by the potential of utilising miRNAs for therapeutic purposes, there are several pitfalls that may prevent their use. Some of these difficulties have already been encountered in incipient attempts to utilise nucleic acids as therapeutics. Initial gene-therapy attempts, where the aim was to restore the function of a defective gene through the addition of a functional copy, generated great excitement in the last decade of the previous century. At this time, huge leaps were made with molecular techniques designed to manipulate and deliver nucleic acids to cells. 97 The first gene therapy trial, designed to correct a genetic defect present in severe combined immunodeficiency disorder resulted in success in two different patients. 98, 99 However, the success of this initial attempt proved difficult to replicate with the majority of successive attempts failing, eventually culminating in disaster in 1999 when two out of ten patients developed leukaemia-like conditions due to the therapy. 100 This was a huge setback to the field of gene therapy and exposed many of the flaws that dogged early attempts, these included the generation of a severe immune response, 100 poor integration of vectors as well as the flipside of this double-edged sword, where lentiviral vectors inserted into and disrupted native genes. 101 Although the initial benefits promised by gene therapy have not yet been reached, some of these problems have at least been partially overcome with a host of therapies currently at various stages of clinical trials. 102, 103 Another approach utilising nucleic acids to provide potential therapeutic benefit, which also arrived to huge fanfare, is the use of antisense via siRNA molecules. As mentioned above, these are similar to miRNAs except that they display perfect complementarity to their respective targets and tend to be from exogenous sources. 104, 105 This method of gene silencing also seems not to have lived up to initial expectations suffering from problems with delivery 105 as well as the activation of an immune response. 106 However, despite these problems, this siRNA-based approach is far from dead in the water with proof of concept studies in non-human primates proving effective in combating the replication of viruses involved in serious pathological conditions. In retrospect, it was probably impossible for initial attempts at the therapeutic utilisation of nucleic acids to live up to the near astronomical expectations that surrounded the field. However, researchers are beginning to overcome problems associated with this type of approach and with more realistic expectations on what these treatments can deliver there is still room in pharmaceutical research for this strategy. miRNAs as relative latecomers to the field of gene therapy will hopefully benefit from the lessons learned both in technical terms and in keeping expectations realistic for such a fledgling technology. Moreover, as native regulators of gene expression they may not suffer from problems such as an exaggerated immune response and their subtle effects on gene expression may make them more amenable to a therapeutic purpose.
Therapeutic potential of miRNAs
Preclinical research has already demonstrated the potential of altering miRNA function to produce a therapeutically relevant outcome in rodents for various different types of disorders, including tumour formation, [110] [111] [112] cardiac disorders 113 and allergyinduced asthma. 114 A number of pharmaceutical companies have emerged where their pipeline is totally based on miRNA-based targets (for example, Regulus (www.regulusrx.com), Santaris pharma a/s (www.santaris.com), MiRNA therapeutics (www.mirnarx.com)). Recently this approach has proven successful in primates with initial work showing intraperitoneal injection of a miR-122 LNA (locked nucleic acid; see section Antagomir-based knockdown) antisense molecule significantly reduced levels of miR-122. 115 Additional work revealed miR-122 to be essential for infection by the hepatitis C virus and high doses of the anti-miR-22 compound over a course of 14 weeks significantly attenuated viral replication as measured by viral RNA levels. 116 Furthermore, this was achieved with no serious side effects and with no adaptive response from the virus. This was the first demonstration that the modulation of miRNA function may be an effective and safe therapeutic strategy in primates. Currently the first miRNA-based therapeutic, a miR-122 inhibitor, based on the above research is in phase-2 clinical trials (www.santaris.com/product-pipeline).
Challenges in delivering miRNAs to the CNS

General aspect
Despite the above data demonstrating the modulation of miRNA function is a feasible therapeutic strategy, the leap from knocking down miRNA function in the periphery to the brain is considerable. The ideal therapy would be an active compound suitable for dispersal in a form that can be administered orally, survives passage through the gastrointestinal system, crosses the blood-brain barrier and produces the desired effect in the desired region, all while remaining non-toxic. The modulation of miRNA functioning within the CNS will likely be achieved through overexpression or reducing function (knockdown) using an antisense oligonucleotide. However, delivery to the brain of viable nucleic acids is particularly difficult compared with peripheral organs. The blood-brain barrier, a network of tight junctions formed by endothelial cells, eliminates the passing of the majority of molecules from circulation into the brain, making the systemic approach (detailed above) for the delivery of nucleic acids almost impossible. [117] [118] [119] The brain is also an extremely heterogenous organ with a large amount of cellular diversity, achieving the desired expression of a specific nucleic acid in a specific part of the brain has historically proved challenging. 118 However, some recent work has demonstrated the possibility of using vectors under the control of cell-specific promoters to produce knockdown limited to particular a region. 120 miRNAs as therapeutic tools suffer from similar practical drawbacks, which other nucleic acids have also suffered. Broadly speaking there are three main hurdles, stability of the nucleic acid in the blood, inability of miRNAs to cross many biological membranes and mediating cell-specific delivery. 121, 122 The design of efficient delivery mechanisms (vectors) has been essential to the development of nucleic acids, for example, siRNA, as potential therapeutics and miRNAs are no exception. Broadly speaking vectors intended for the delivery of nucleic acids can be classified as either viral or non-viral. Viral vectors (retroviruses, adenoviruses and so on) are efficient facilitators of transfection allowing for integration of the vector into the host chromosome producing stable expression. 123 However, these are difficult to produce on a large scale and even more importantly they are hampered by a serious safety burden detailed above. 100, 123, 124 Synthetic and non-viral methods are being actively pursued as potential strategies to overcome these problems, 124 but these delivery methods also need to overcome many barriers to become therapeutically viable. 124 In addition to the choice of vector, another critical choice is the route of administration. As mentioned above, an orally active therapeutic is the most desired but also most challenging. Other routes that can be considered are more invasive and obviously the potential benefits and risks will have to be carefully considered. These include intravenous injections, osmotic minipumps and direct injections to the brain. Currently it is possible to envisage that while such invasive strategies may be beneficial for the treatment of some severe neurological disorders such as Huntington's Disease, their widespread utility for psychiatric disorders is limited. That said, there is an increasing move towards employing invasive technologies such as deep-brain stimulation to treat severe treatment refractory patients with major depression or anxiety disorders. [125] [126] [127] The utilisation of miRNAs as therapeutics will have to overcome additional difficulties, which may be unique to each particular miRNA and any therapies utilising miRNAs will each have to be considered on an individual basis. The establishment of an appropriate dose of a particular miRNA may be a particularly complex issue as repression by miRNAs is modest up to a point at which increased levels of a particular miRNA generate a type of molecular switch where protein production is highly repressed. 128 Moreover, the levels of repression induced by specific miRNAs varies greatly among cell type, 128 further adding to the need to deliver the miRNA to a specific cell or group of cells. Furthermore, due to the sequence-specific manner by which miRNA mediate their regulatory effects, 78 caution will need to be taken to ensure non-target mRNAs are not repressed to deleterious consequences by altering the levels of a particular miRNA.
There are two basic choices when deciding on modulating the function of a particular miRNA. This will either be knocking down or increasing the levels of a particular miRNA available to regulate a particular mRNA.
Antagomir-based knockdown
In vivo knockdown of mRNA targets using antisense nucleotides in rodent models has already been achieved in the periphery 129 and moreover, the brain, [130] [131] [132] [133] which has led to therapeutically relevant behaviour outputs. In these studies, siRNA constructs designed to target the mRNA of genes previously implicated in the neurobiology of depression, DAT 131, 132 GRM7 130 and serotonin transporter (SERT) 131, 133 were administered to the rodent brain. This produced an hyperlocomotor response following reduction of DAT expression, 131, 132 an antidepressant effect in the forced-swim test after targeting SERT mRNA, 131, 133 whereas knocking down of GRM7 mRNA led to an impairment to Pavlovian fear learning. 130 To achieve the in vivo knockdown of miRNAs, Krutzfeldt et al. 134 developed antagomirs, chemically modified, cholesterol-conjugated singlestranded RNA analogues (LNAs) complementary to miRNAs, which bind to and prevent miRNAs from mediating their gene-silencing effects. These have already been used to knockdown miRNAs in both the periphery 134 and brain. 135, 136 However, success in rodent models does not always translate to the human situation, thus the recently demonstrated knockdown of miRNAs in primates is a major step forward toward miRNA-based therapeutics in humans. 115 The fact that altering miRNA expression in the brain produced a therapeutically relevant behavioural change, 135, 136 is extremely promising, however, it needs to be noted that knockdown of miRNAs were achieved through invasive surgical techniques, which would only be therapeutically relevant in severe disease cases. Another drawback with this type of approach would be the requirement to continuously administer these antagomirs to achieve a sustained knockdown.
Overexpression
Delivery of RNAi molecules in vivo has been possible for years, with the use of viral vectors driven by strong promoters being a popular choice. 137, 138 This technique has already proved successful with miRNAs in rodent models producing therapeutically relevant outcomes in the areas of drug addiction and depression-like behaviour. 135, 139 The altering of miRNA expression has great potential not only in treating disease states where a clear aberrant miRNA expression is present but also in treating disorders where protein-coding genes are implicated. It may be miRNAs subtle effects on the translation of mRNAs may make them uniquely suited to treating disorders where only a mild change to expression is desired.
Evidence demonstrating the potential of targeting miRNAs to treat depression Acute and chronic stress alter miRNA-expression profiles in a brain region-dependent fashion Stress is one of the major predisposing factors for anxiety and mood disorders. Chronic stress and stress in early life can create pathological changes in the brain that impair behavioural and physiological responses. [140] [141] [142] These changes can predispose certain individuals to psychiatric diseases, such as depression and anxiety disorders. 96, [143] [144] [145] If miRNAs have a role in the adaptive (and maladaptive) response to a psychological stressor then it may be the case that targeting miRNAs may be a viable strategy for the treatment of stress, which may predispose individuals to mood and anxiety disorders.
One of the first studies to highlight the potential importance of miRNAs in the stress response demonstrated chronic immobilisation stress in rats produced region-specific changes to miRNA levels. 146 miRNAs were differentially affected between the CA1 area of the hippocampus and central nucleus of the amygdala following restraint stress. Furthermore, acute (1 day) and chronic restraint stress (14 days) produced different miRNA-expression profiles in the two regions with very little overlap. 146 The authors note that chronic stress produced a greater number of significant changes to miRNA levels than acute stress and that most of these changes represented decreases. In contrast to these results, a similar experiment found differing results when they analysed miRNA expression in the pre-frontal cortex of CD-1 mice following restraint stress. 147 In these studies, a large increase (as opposed to a decrease in the previous experiment discussed) in expression levels of miRNAs following a single restraint stress (1 session of 2 h), however, only a modest change following repeated restraint stress (5 sessions over 5 days). 147 A source of the contrasting results between these two experiments may be methodological differences as both studies used a different experimental species and very different restraint procedures, with Meerson et al. 146 subjecting rats to 14 days of restraint for 4 h a day, and Rinaldi et al. 147 using CD1 mice and a much milder restraint procedure consisting of 2 h for 5 days. 
Additionally, the original microarray genechips used for the profiling study were very different in both studies (Meerson et al. 146 utilised the mirVana oligo set to construct an array in house, whereas Rinaldi et al. 147 used a miRCURY LNA microRNA array; Exiqon A/S, Vedbaek, Denmark), which could affect the final results.
Although currently there is conflicting data surrounding which miRNAs are altered as well as the magnitude of changes (both in number of miRNAs and the levels as to which these are changed), it is becoming increasingly clear that psychological stress impacts on miRNAs levels with further experiments being required to achieve more definitive conclusions on which particular miRNAs are altered and how this leads to downstream changes affecting cellular function.
It is tempting to speculate that these changes are part of an adaptive homoeostatic response by which an increase to selective miRNAs serves the dual functions of receding changes to mRNA levels, that may lead to detrimental effects if expression remained high and also to activate a program of gene expression that will work in concert to produce an adaptive response to the stressor.
Both of these studies demonstrate stress-induced changes to miRNA levels are brain-region specific with very little overlap occurring between the different brain regions analysed (CA1 region of the hippocampus, central nucleus of the amygdala and pre-frontal cortex) both within and between the studies. This would not be unexpected as these very different stress-induced miRNA profiles would lead to very different gene-expression patterns, which would likely be uniquely suited to that particular brain regions function in the stress response. This region specific and differential response to acute and chronic stress is mirrored in mRNA-expression patterns [148] [149] [150] [151] [152] so it may be that changes to miRNA expression serve to influence mRNA expression patterns, which can in turn influence miRNA-expression patterns creating an intricate regulatory loop.
Chronic immobilisation stress is not the only stress model where the role of miRNAs has been investigated. Maternally separating rat pups from their mothers is used as a model of early life stress and leads to a host of physiological alterations, [153] [154] [155] increased 5-HT turnover and an exaggerated hypothalamic-pituitary-adrenal axis response to restraint stress. 156 Uchida et al. 156 went on to demonstrate maternally separated animals have increased expression of the transcription factor REST4 in the pre-frontal cortex and it has been previously demonstrated that REST4 regulates several brain-enriched miRNAs. 157, 158 Moreover, several of these miRNAs including mir-132, -124-1, -9-1, -9-3, -212 and -29a are increased in the pre-frontal cortex of maternally separated rats. 156 One can speculate that the stress-induced increase to REST4 leads to a host of gene-expression changes including the upregulation of the above-mentioned miRNAs. These will then go on to repress their target mRNAs leading to a host of downstream changes greatly amplifying the original signal.
The above data suggest changes in miRNA expression represent an integral part of the stress response. It is likely that miRNA levels change in response to stress to act in an adaptive nature altering geneexpression patterns to help combat the psychological stressor. However, exaggerated or prolonged levels of stress could possibly lead to prolonged changes to miRNA expression, which may ultimately lead to maladaptation. In stress disorders where a clear change to miRNA levels has been identified, it may be possible to normalise the changed miRNA levels reducing the prolonged effects of stress. Furthermore, miRNAs may also be used to fine tune expression of mRNAs involved in stress broadening their scope as a therapeutic tool.
Genetic differences in miRNA expression influence the coping response
The genetic loci of miRNAs are subject to similar regulatory controls as mRNAs, being located in polycistroinic units under the control of promoters regulated by transcription factors and mainly being transcribed by RNA polymerase III. [54] [55] [56] Therefore, it is very likely that individual differences in miRNAexpression patterns exist and these will influence an individual's reaction to a stressor. Some early preclinical work has demonstrated support for this hypothesis.
The stress-sensitive F344 rat strain displays an exaggerated HPA axis response over 14 days of restraint stress, whereas the control Sprague Dawley strain demonstrates a gradual decrease in HPA activity. 159 This is in line with other data demonstrating F344 rats display both an exaggerated-HPA response to chronic mild stress 160 and increased anxiety in the elevated plus maze. 161 This strain was found to have increased levels of the miRNA miR-18a in the paraventricular nucleus (PVN) of the hypothalamus, which was found to target the glucocorticoid receptor (GR). Increased levels of miR-18a in the PVN is a likely contributing factor to the genetic susceptibility to stress displayed by these rats.
When a group of rats are subjected to repeated inescapable shock, a subgroup will fail to show escape-orientated behaviour even when the possibility of escape exists. 162, 163 This phenomenon is termed learned helplessness (LH) and has been used as a model of the vegetative symptoms of depression. [162] [163] [164] [165] [166] It has been previously shown that Holtzman rats who do not develop this LH behaviour (NLH (non-learned helplessness) rats) show numerous hippocampal mRNA changes when compared with LH and naïve rats. 167 This increased mRNA response in NLH rats may represent a coping mechanism that serves to produce a physiological response allowing it to overcome stress. A similar pattern has been demonstrated in the hippocampal miRNA response with NLH rats showing a large change to miRNA levels (mainly a decrease), whereas LH rats showed a similar miRNAs as targets for treatment of anxiety and depression RM O'Connor et al yet blunted response pattern. 168 This demonstrates that underlying genetic differences in miRNA-expression pattern are associated with an individual's ability to develop a behavioural-coping response to a particular stressor, further work, involving additional behavioural paradigms and the modulation of miRNA levels in vivo need to be conducted to strengthen (or reject) the case for a causative relationship between miRNA-expression levels and behavioural coping responses (or lack thereof). If one exists, it may be possible to use miRNAs to induce a pattern of gene expression, which would allow for better coping in a stressful situation.
Predicted mRNA targets of miRNAs involved in the stress response modulate physiological response to stress Although expression-profiling studies following a stressor can indicate the potential involvement of a miRNA in the adaptive response to stress, it is ultimately their regulatory effects on their mRNA targets that dictate their influence on cellular function.
Following miRNA-expression profiling, bioinformatic analysis has been designed to predict the mRNA targets of the miRNAs showing altered expression response to stress. Interestingly, one of the most commonly found class of targets are transcription factors. 146 A similar picture emerged from other studies focused on the role of miRNAs involved in LH behaviour where a large number of transcription factors are also regulated. 168 This overrepresentation of transcription factors as targets may make miRNAs very attractive therapeutic as altering their expression may serve to alter the expression of a whole network of genes. A striking example of this regulation of transcription factors by miRNAs is Creb1, which regulates a host of cellular functions. [169] [170] [171] Of the miRNAs altered in LH compared with NLH rats, four (all of which were upregulated) are predicted to regulate Creb1. 168 Furthermore, it is known that LH have reduced levels of Creb1, which can be reversed by chronic antidepressant treatment. 172 Although the authors do point out that the increased levels of hippocampal miRNAs targeting Creb1 in LH rats are unlikely to be the sole determining factors of Creb1 levels, 168 it is likely they play a role in its downregulation. In this instance, the upregulation of miRNAs that target Creb1 likely contributes to the decreased Creb1 levels seen in LH rats. Using antagomirs to reduce the inhibitory effects of these miRNAs may be a strategy that would mimic some of the downstream effects of antidepressants, which serve to increase Creb1 levels.
As discussed above, both miR-134 and miR-183 display increased expression in the amygdala due to acute stress, whereas chronic stress decreases miR-134 expression while leaving miR-183 unchanged. 146 miR-134 and miR-183 share the splicing factor, SC35 as an mRNA target confirmed through in vitro studies. Previously it has been shown that SC35 is increased in the pre-frontal cortex of mice subjected to 4 days of swim stress 173 and was shown in vitro to promote the splicing of AchE (acetylcholinesterase) from the dominant AChE-S to the stress-induced AChE-R variant. A reduction in amygdalar miR-134 would relieve the repression of SC35 expression, which in turn would induce a selection towards the increased levels of stress-induced AChE-R variant. Initial target data is suggesting miRNAs likely regulate a large number of gene-expression regulators, including transcription and splicing factors. Although altering a miRNA may produce a small initial regulatory effect on its initial target mRNA, this may lead to a much greater downstream effect due to altering the expression of other regulators of gene expression.
As mentioned above, F344 rats possess lower expression of the GR protein but not mRNA in the PVN of the hypothalamus. 159 A reduction in GR would lead to a decreased level of negative feedback on the HPA axis contributing to the exaggerated HPA response seen in the strain. Sequence data predicts the 3 0 UTR of GR mRNA possess multiple miRNAbinding sites, 174 and in addition Uchida et al.
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demonstrate miR-18a negatively regulates GR in cultured neuronal cells. Furthermore, they show F344 rats have increased miR-18a expression in the PVN compared with the SD strain. Taken together, this data would suggest that increased miR-18a in the PVN of F344 rats inhibits translation of GR mRNA to protein, thus contributing to the exaggerated HPA response. Knocking down of miRNAs may be a viable strategy to increase GR levels, which would lead to an overall suppression of the HPA response. The above data demonstrate miRNAs, which show expression changes due to stress, are predicted to regulate mRNA targets, which have themselves been implicated in stress-induced depressive behaviour. Altering the levels of these miRNAs will lead to changed levels of these mRNAs, which may produce therapeutically relevant benefits.
Human genetic studies highlighting the potential role of miRNAs in depression Genetic evidence is beginning to show genetic differences in miRNA expression contribute to the susceptibility to the onset of depression. The first study to examine the potential link between polymorphisms in miRNA genes showed a statistically significant link between a polymorphism in the miR30e gene and the onset of major depressive disorder. 175 Although this was a very ethnically limited group, these results were an important indication that differences with miRNA genes can contribute to the onset of psychiatric disorders. Functional data regarding miR-30e show it can suppress cell growth, 176 and it has previously been demonstrated the same polymorphism was also linked with the onset of schizophrenia. 177 Furthermore, post-mortem studies reveal increased levels of miR-30e in patients with schizophrenia. 178 So although it is by no means confirmed that miR-30e has a role in brain miRNAs as targets for treatment of anxiety and depression RM O'Connor et al development, early evidence is pointing to it having a significant role in the genesis of mental disorders and may be an interesting target to consider for therapeutic intervention.
Disruption to the circadian rhythm is being viewed more and more as a contributing factor the onset of depression. 179, 180 A genetic-association study has shown a polymorphism in the pre-miR-182 gene to be significantly linked with major depression and late insomnia. 181 Interestingly, this miRNA was predicted to regulate the CLOCK gene, which itself has been linked to insomnia and depression, [182] [183] [184] which the authors confirmed in vitro through the use of a luciferase reporter. 181 These data indicate aberrant miRNA expression may contribute to the dysregulation of genes associated with maintaining the correct circadian rhythm and through this may contribute to the onset of depression. Targeting these miRNAs may help to reset the circadian rhythm and reduce depressive symptoms.
It may be possible to alter the expression of miRNAs for which an altered expression profile has been shown to influence the onset of depressive disorders. By normalising the levels of these miRNAs, it may be possible to produce therapeutically relevant outcomes.
Specific miRNAs are the targets of psychoactive drugs
As discussed above, our current knowledge regarding the molecular underpinnings of the therapeutically relevant mechanisms underlying current treatments for psychiatric disorders remain incomplete. Although in many cases the immediate biochemical effect is known (for example, inhibiting the reuptake of serotonin and/or noradrenaline), the downstream molecular effects, which likely mediate much of the therapeutic benefit, remain unknown. It is now becoming clear that alteration to miRNA levels may be one of the therapeutically relevant downstream effects of antidepressants. The fact that currently available therapeutics for the treatment of mood disorders function to alter miRNA levels supports the idea of targeting them directly to produce therapeutically beneficial effects.
One of the first studies to investigate if miRNAs are potentially targets of psychoactive drugs investigated if chronic treatment with the mood stabilisers, lithium and sodium valproate, could influence hippocampal miRNA levels in Wistar Kyoto rats. 71 It was found that lithium altered 37 miRNAs whereas sodium valproate altered 31. Interestingly of these, a similar change was seen in 9 miRNAs suggesting these miRNAs may be especially relevant to the mood-stabilising effects of these drugs. 71 To prioritise predicted targets for follow-up analysis, the authors cross referenced this list with the Welcome Trust Case Control Consortium list for likely targets involved in bipolar disorder and found six that were also regulated by the miRNA targets (CAPN6, DPP10, ESRRG, FAM126A, GRM7 and THRB). Of these, it was found that hippocampal protein levels of GRM7, DPP10 and THRB were upregulated, which was in line with microarray data showing several miRNAs predicted to regulate these mRNAs were downregulated. Indeed, early work conducted in our laboratory has begun to shed light on the effect of lithium and chronic immobilisation stress on miRNA function. We found that chronic immobilisation stress altered hippocampal miR-34c levels and amygdalar miR-15a levels with lithium reversing these changes but only in a stress-specific fashion. 185 It may be that certain psychoactive drugs mediate their benefit by reversing disease-induced changes to miRNA expression in specific brain regions. To further add credence to the hypothesis that these mood stabilisers function through altering the levels of specific miRNA levels, it will be necessary to alter these miRNAs in vivo and examine their effect in pre-clinical models of depression.
miR-16 has been shown to regulate the SERT in vivo using a luciferase reporter assay, 139 and interestingly, has been shown to be involved in determining if a neuroectoderaml cell line follows a serotonergic or noradrenergic fate. 139 In cells that differentiate into serotonergic cells, miR-16 levels remain unchanged, however, cells that develop along the noradrenergic pathway show increased miR-16 levels and reduced SERT levels. 139 It is likely that miR-16 contributes to the development and maintenance of a noradrenergic phenotype by repressing translation of the SERT (and possibly other) mRNAs. Furthermore, infusion of fluoxetine into the raphe nucleus increases miR-16 expression, which would contribute to the selective serotonin-reuptake inhibitors inhibitory effects on SERT function through repression of mRNA translation. 139 When miR-16 was infused directly to the raphe it was found to have an antidepressant-like effect in the forced-swim test (FST). 139 Interestingly, when miR-16 levels were analysed in the locus coeruleus following chronic fluoxetine treatment they were found to be decreased. 139 Moreover, reducing miR-16 in the locus coeruleus using a miR-16 antagomir led to an antidepressant effect in the forced-swim test. 139 This was a very significant finding, demonstrating that one of the most commonly used antidepressants likely employed altering of miRNAs as a therapeutically beneficial mechanism. Furthermore, fluoxetine differentially affected miR-16 levels in the raphe nucleus and locus coeruleus. These early data demonstrate targeting specific miRNAs in specific brain regions may be a more direct route to achieving an antidepressant effect. It also highlights the regional specificity that may be required as increasing a miRNA in one region may have the opposing effect in a different region. This poses a major challenge for drug development.
miRNAs have been shown to be involved not only in the therapeutically relevant mechanisms of psychoactive drugs but also in the negative effects including mediating drug dependence. It was found miRNAs as targets for treatment of anxiety and depression RM O'Connor et al that striatal miR-212 was increased in rats trained to self administer cocaine, and that this increase decreased the motivational properties of the drug by increasing the stimulatory effects of the drug on CREB signalling. Moreover, overexpression of miR-212 in the striatum decreased cocaine-seeking behaviour, whereas knockdown of striatal miR-212 increased the addictive effects of cocaine. miRNAs may represent a novel avenue of therapeutics for treating drug addiction. 135, 136, 186 The above data showing currently used medications for the treatment of psychiatric disorders employ alterations to miRNA levels as possible downstream therapeutic mechanisms are extremely promising. By directly targeting these miRNAs, it may be possible to produce a more robust antidepressive effect possibly more rapidly and with reduced side effects.
miRNAs and anxiety
To date, there has been little evidence gathered demonstrating miRNAs involvement in pathological anxiety. As far as we are aware, there has been no preclinical study that directly examines the role miRNAs have in pathological anxiety. However, based on the ubiquitous role of miRNAs in CNS function it is very likely they are involved in the neurobiology, which underlies pathological anxiety and indeed there is a limited amount of evidence suggesting so. As in section Overexpression, the F344 rat strain is a stress-sensitive rat strain that displays anxiogenic behaviour in pre-clinical behavioural models. 161, 187 The increased levels of miR-18a in the PVN of F344 rats may contribute to the decreased levels of GR that in turn likely leads to increased HPA activity and increased anxiety. Further studies will need to be conducted on the influence miRNAs have in the F344 rats levels increased anxiety. As mentioned above, miR-16 is a target of the selective serotonin-reuptake inhibitor fluoxetine and has itself been shown to mediate its antidepressant effects. 139 Selective serotonin-reuptake inhibitors are also first-line treatment for the treatment of a number of anxiety disorders 11, 13, 14 and modulation of miR-16 expression is a potential route by which these drugs mediate their therapeutic effect. In addition to treating depression, directly targeting miR-16 in relevant brain regions may also serve as a more direct route to the treatment of anxiety.
Genetic-association studies have also been utilised to examine the influence polymorphisms in miRNAs loci have in the development of anxiety. Previously it has been shown that that single-nucleotide polymorphisms in the 3 0 UTR of the neurotrophinreceptor 3 gene (NTRK3) might contribute towards an obsessive compulsive disorder phenotype. 188 It was found that a single-nucleotide polymorphism in the functional target site of the miRNA, miR-485-3p, was significantly associated with the hoarding phenotype of obsessive compulsive disorder. Furthermore, this particular study identified two new rare variants in the 3 0 UTR of NTRK3 present in one patient with panic disorder, one located in the target site for miR-765 and the other in the target site for both miR-509 and miR-128. Using in vitro analysis, the authors show these two variants greatly influence miRNA-mediated regulation of NTRK3. The same group went on to show different single-nucleotide polymorphisms associated with panic disorders tag the miRNA loci of several miRNAs, namely miR-22, miR339, miR-138-2, miR-488, miR-491 and miR148a. 189 The authors then prioritised potential mRNA targets for functional analysis by cross referencing with candidate genes for panic disorder 190 and found miR-138-2, miR-148a and miR-488 repress GABRA6, CCKBR and POMC mRNA in vitro, respectively and miR-22 regulates four other candidate genes namely BDNF, HTR2C, MAOA and RGS2. In the context of obsessive compulsive disorder, it is worth considering studies on Tourette's syndrome, a debilitating psychiatric disorder characterised by involuntary motor and vocal tics, 191, 192 which displays a high level of comorbidity with obsessive compulsive disorder and depression. 193 It has been shown that the binding site for miR-189 located in the 3 0 UTR of SLITRK1 mRNA, a potential candidate gene influencing the onset of Tourette's syndrome, was found to have a substitution in two unrelated individuals with Tourette's syndrome that increased the level of repression on SLITRK1.
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Fear extinction is the gradual reduction of the fear response due to repeated exposure of non-reinforced fear-related cues allowing for the adaptive control of conditioned fear responses. 195 This phenomenon has generated a great deal of research due to its relevance to human phobias and post-traumatic stress disorder. 195, 196 Briefly outlined, the procedure involves the repeated pairing of an innocuous cue such as a brief tone with an unpleasant stimulus such as a shock delivered via a metal grid in the floor. Following numerous presentations of these two stimuli together, the animal will eventually display a fear response, such as freezing, even when the innocuous tone is produced alone. Repeated presentations of the tone alone will eventually lead to the disassociation of the two stimuli. A recent study demonstrated that miR-143 showed increased levels in the infralimbic prefrontal cortex, a brain region critical to fear-learning processes, however, this miRNA showed no further changes to expression following fear-extinction learning, 197 suggesting this miRNA is involved in the original pairing of the cues but not in the extinction of this pairing. Interestingly, a separate miRNA, miR128b showed no significant increase due to the original fear learning but showed a dramatic change (B4-fold increase) in response to fear extinction. Furthermore, when fear extinction was retarded using the NMDA receptor antagonist MK-801, no changes to miR-128b levels were seen. Moreover, when miR128b function was disrupted via a lentiviral construct delivered to the infralimbic pre-frontal cortex, fear miRNAs as targets for treatment of anxiety and depression RM O'Connor et al extinction was impaired, whereas conversely, increasing levels of miR-128b in this region enhanced fear extinction. The authors also showed this effect was specific to the IFLPFC as infusion of miR-128 into the prelimbic pre-frontal cortex had no effect on fear extinction. Although these are early results, miRNAs may be intimately involved in fear-extinction processes and further research may allow for miRNAbased therapeutic interventions for post-traumatic stress disorder and severe phobias to be considered.
Although only limited studies have looked at the possibility of miRNA expression influencing the onset of a pathological anxiety phenotype in clinical populations, there is some preliminary evidence to support this. If altered miRNA levels demonstrate to influence the onset of anxiety it may be possible to treat anxiety by changing miRNA-expression levels.
Conclusions and perspectives
Since their discovery and original characterisation, the ubiquitous nature of miRNA involvement in various biological processes has become clearer. They have key roles in governing virtually all processes in the CNS, making it very likely that altering their function will produce many downstream changes at a physiological and behavioural level.
It is clear that drug discovery efforts for the treatment of mood disorders need to move from the traditional focus on monoaminergic systems towards novel targets based on a rational drug discovery approach. As ubiquitous regulators of so many physiological processes including in the CNS, miRNAs represent a promising class of targets whose therapeutic potential to date remains almost completely unexplored.
Although research efforts to characterise the role these small RNAs have in depression and anxiety disorders is still in its infancy, a wealth of evidence has already been collected showing aberrant miRNA expression can influence the onset of both anxiety and depression (Table 1) . It is through their sequencespecific regulatory effects on mRNAs that miRNAs mediate their ultimate cellular effects, and in vitro, in vivo and in silico work has shown miRNAs have the capacity to regulate an enormous number of mRNAs that have important roles in a host of processes, which have been linked to the onset of depression of anxiety, including regulation of monoamine transporters, circadian rhythm and synaptic plasticity.
miRNA expression has been shown to be responsive to a psychological stressor and early research suggests endogenous genetic differences in miRNAexpression levels contribute to the onset of anxiety and depression. Some early work to identify the mRNA targets of these miRNAs revealed many of them have been previously highlighted as possibly contributing to the onset of anxiety and depression. Targeting these miRNAs could prove a beneficial therapeutic avenue. Some of the most striking evidence supporting the concept of targeting miRNAs to treat mood disorders is the fact that currently available medications indicated for the treatment of these disorders already serve to alter miRNA expression. Directly targeting miRNAs may be a more beneficial route that may lead to a more rapid therapeutic effect with fewer side effects. Furthermore, targeting miRNAs holds promise as a treatment strategy not just in situations where a clear aberrant miRNA-expression profile has been detected but also in cases where altered mRNA or indeed aberrant protein levels are seen as the underlying molecular pathophysiology. Given a single miRNAs ability to regulate many different mRNAs, targeting a miRNA may prove a very useful strategy where changes to levels in many different proteins have been identified as contributing to the molecular pathophysiology. However, it is worth noting that the amplification ability of targeting a single miRNAs to affect multiple downstream targets could also increase the susceptibility to side effects and the safety profile of any new medication needs to be rigorously tested. Nonetheless, although being early days in miRNA-based therapeutic development, a miRNA-based therapy has already been shown to be safe in primates and has entered phase-II clinical trials. Although this treatment is not specific to the brain, it highlights the potential safety and therapeutic benefits of using miRNAs.
However, with the application of any new technology to the treatment of human disorders there are numerous issues that will need to be considered to ensure the therapeutic potential of this technology reaches fruition. One of the main issues will be the translating of data from pre-clinical models to the human situation, this is especially difficult with psychiatric conditions owing to the complex nature of these disorders, with many aspects being exclusive to the human condition. 198 It is imperative that research using animal models is conducted in tandem with clinical research efforts to confirm the involvement of a miRNA in a pathological condition. Additionally, despite the huge leaps that are being made in understanding the biological significance of individual miRNAs, this will not translate to advances in therapies without parallel advances in pharmaceutical biotechnology to ensure that any potential therapy is formulated appropriately without toxicological issues. Duration of treatment is another important issue that will have to be carefully considered and will likely depend on the individual miRNA and disease in question. Furthermore, due to the enormous and almost completely untapped therapeutic potential of miRNAs, there is an everexpanding commercial interest in the application of this technology. It is imperative that investors be aware of the patent landscape that exists surrounding this technology. 199 Concomitant with being granted a patent for the therapeutic use of a particular miRNA is the proof of novelty and utility, which are ambiguous concepts likely to generate much debate in the coming years. To promote the exploitation of this miRNAs as targets for treatment of anxiety and depression RM O'Connor et al miR-509 SNP found in a patient with panic disorders and shown to regulate NTRK3 (which has been implicated in contributing to panic disorder)
Muinos-Gimeno et al. miR-765 SNP found in a patient with panic disorders and shown to regulate NTRK3 (which has been implicated in contributing to panic disorder)
Muinos-Gimeno et al. miR-9 Upregulated expression in the frontal cortex following acute stress Rinaldi et al.
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Upregulated expression in the medial pre-frontal cortex following maternal separation Uchida et al. technology to its maximum benefit, the conditions dictating the success of patent applications will need to be broad enough to allow commercial entities that have sufficiently contributed enough knowledge to satisfy both novelty and utility to recoup initial investments, while at the same time preventing the granting of patents that act as place holders until a real-world utility can be established as this would stagnate research efforts. 199 (For a more extensive review on miRNA patents to date, please see ref . 199) .
Overall, targeting miRNAs clearly represent a novel approach that holds great promise in neuropsychiatry.
Research into these small molecules should be prioritised so that someday they may represent a fully realised, truly novel therapeutic strategy for the treatment of mood and anxiety disorders. Time will tell whether these, like the red rose in Wilde's short story, 200 hold the promise of supplanting all other strategies for happiness.
